TEL AVIV, Israel, August 7, 2017 /PRNewswire/ --
Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of stem cell selection technology, announced today that Locust Walk was engaged to seek strategic licensing deals and global pharma partnerships in order to kick-start the commercialization of Cellect's ApoGraft as an innovative platform for stem cells selection for all indications and from all sources of cells. Among others, the Company believes this platform is expected to become a major cornerstone development tool for both pharma companies and medical research centers through licensing of Cellect's IP.
Locust Walk's mandate is to identify relevant licensors and assist Cellect in closing potential licensing deals and strategic business collaborations with pharma and medical device companies as well as research and clinical centers that may potentially result in licensing of AppoGraft for stem cells based therapeutics R&D purposes.
Cellect's ApoGraft technology can be utilized immediately to help thousands of research centers globally engage in adult stem cells based therapeutics by providing them with a simplified and cost efficient method to isolate stem cells for use as a raw material for a wide range of stem cells based therapeutics. Before Cellect's ApoGraft, such procedures were extremely complex, inefficient and required substantial resources in both cost, time and infrastructure. ApoGraft will be used to significantly advance the use of stem cells across multiple therapeutic indications as well as research and biobanking purposes.
Cellect's CEO, Dr. Shai Yarkoni commented, "Similar to the successful collaboration Cellect has with Entegris (NASDAQ: ENTG), we intend to secure our capabilities to supply all of the players in the stem cell field with the capabilities to produce and sell stem cell based medical products for a multi-billion dollar market. Cellect intends to become a major player in this fast growing field and therefore we are committed to a global scale campaign for business development with our new partner - Locust Walk."
Cellect chairman, Mr. Nuriel Chirich Kasbian stated, "After years of work, we are close to realizing the first commercial applications of ApoGraft. We chose Locust Walk to help us unlock the value of ApoGraft for both medical research companies and shareholders."
About Cellect Biotechnology Ltd.
Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications.
The Company's technology is expected to provide pharma companies, research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stem cells related treatments and procedures. Cellect's technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.
About Locust Walk
Locust Walk is a leading life sciences transaction advisory firm focused on biopharmaceutical and medical technology companies. Its team of experienced professionals fuels the growth of promising companies at every stage by connecting the right products, the right partners and the most attractive sources of capital - driving innovation for growth and transformative results.
Locust Walk was founded in 2009 and currently has offices in Boston; San Francisco; Tokyo, Japan and Cologne, Germany. Over the past two years, Locust Walk has completed many transactions for its clients around the world. For further information, please visit http://www.locustwalk.com.
Forward Looking Statements
This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our expectation regarding the market opportunity of ApoGraft potential licensing and other collaborations, our beliefs about the future integration of our technology into the production procedures of stem cell-based products, the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer
SOURCE Cellect Biotechnology Ltd.